Polymeric Nanoparticles Enable Targeted Visualization of Drug Delivery in Breast Cancer

We report the coencapsulation of fluorocoxib Q (FQ) and chemocoxib A (CA) in micellar nanoparticles (FQ-CA-NPs) of a new PPS<sub>135</sub>-<i>b</i>-POEGA<sub>17</sub> diblock polymer, which exhibited a hydrodynamic diameter of 109.2 ± 4.1 nm and a zeta potential (ζ) of -1.59 ± 0.3 mV. The uptake of FQ-CA-NPs by 4T1 mouse mammary cancer cells and intracellular cargo release were assessed by fluorescence microscopy that resulted in increased fluorescence in 4T1 cells compared to cells pretreated with celecoxib. The viability of primary human mammary epithelial cells (HMECs) or 4T1 mouse mammary carcinoma cells treated with FQ-CA-NPs were assessed, which showed decreased growth of 4T1 breast cancer cells but showed no effect on the growth of primary human mammary epithelial cells (HMECs). Intravenous dosing of FQ-CA-NPs in mice enabled ROS-induced cargo (FQ and CA) release and fluorescence activation of FQ and resulted in increased fluorescence in breast tumors compared to the tumors of animals pretreated with tempol or celecoxib, and minimum fluorescence was detected in the tumors of animals treated with nothing or empty-NPs. In addition, tumor tissues from treated animals were analyzed <i>ex vivo</i> by liquid chromatography-mass spectrometry (LC-MS)/MS, and identified increased levels of cargo delivery and retention in the tumor compared to tempol- or celecoxib-pretreated animal tumors. These <i>in vivo</i> and <i>ex vivo</i> results confirmed the targeted delivery of loaded NPs followed by ROS-mediated cargo release and fluorescence activation for targeted visualization of drug delivery in breast tumors and CA-induced therapeutic effect in an <i>in vivo</i> tumor growth inhibition assay and an <i>ex vivo</i> hematoxylin and eosin (H&E) staining of tumor tissues. Thus, coencapsulation of FQ and CA into polymeric micellar nanoparticles (FQ-CA-NPs) enabled their ROS-sensitive release followed by fluorescence activation and COX-2-dependent tumor targeting and retention in the visualization of CA delivery in solid breast tumors.

Authors

Institutions

Publication Details

Journal
Molecular Pharmaceutics
Published
2025-04-21
DOI
https://doi.org/10.1021/acs.molpharmaceut.4c00695
Citations
1
Primary Topic
Nanoparticle-Based Drug Delivery
Type
article
Field-Weighted Citation Impact
0.60

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Polymeric Nanoparticles Enable Targeted Visualization of Drug Delivery in Breast Cancer

Connor G. Oltman, Md. Saidur Rahman, Rebecca S. Cook, Md. Jashim Uddin et al.
1 citations
Molecular Pharmaceutics
Nanoparticle-Based Drug Delivery
0.60
article

Polymeric Nanoparticles Enable Targeted Visualization of Drug Delivery in Breast Cancer

Connor G. Oltman, Md. Saidur Rahman, Rebecca S. Cook, Md. Jashim Uddin, Thomas A. Werfel, Justin H. Lo, Philip J. Kingsley, Brenda C. Crews, Mukesh Kumar Gupta, Craig L. Duvall, Lawrence J. Marnett, Abu Asaduzzaman, Eva F. Gbur, Farhana Nazmin, Ahan Jashim, Mohammed T. Mohyuddin, Jamie E. Klendworth
article en
1 citations

Abstract

We report the coencapsulation of fluorocoxib Q (FQ) and chemocoxib A (CA) in micellar nanoparticles (FQ-CA-NPs) of a new PPS<sub>135</sub>-<i>b</i>-POEGA<sub>17</sub> diblock polymer, which exhibited a hydrodynamic diameter of 109.2 ± 4.1 nm and a zeta potential (ζ) of -1.59 ± 0.3 mV. The uptake of FQ-CA-NPs by 4T1 mouse mammary cancer cells and intracellular cargo release were assessed by fluorescence microscopy that resulted in increased fluorescence in 4T1 cells compared to cells pretreated with celecoxib. The viability of primary human mammary epithelial cells (HMECs) or 4T1 mouse mammary carcinoma cells treated with FQ-CA-NPs were assessed, which showed decreased growth of 4T1 breast cancer cells but showed no effect on the growth of primary human mammary epithelial cells (HMECs). Intravenous dosing of FQ-CA-NPs in mice enabled ROS-induced cargo (FQ and CA) release and fluorescence activation of FQ and resulted in increased fluorescence in breast tumors compared to the tumors of animals pretreated with tempol or celecoxib, and minimum fluorescence was detected in the tumors of animals treated with nothing or empty-NPs. In addition, tumor tissues from treated animals were analyzed <i>ex vivo</i> by liquid chromatography-mass spectrometry (LC-MS)/MS, and identified increased levels of cargo delivery and retention in the tumor compared to tempol- or celecoxib-pretreated animal tumors. These <i>in vivo</i> and <i>ex vivo</i> results confirmed the targeted delivery of loaded NPs followed by ROS-mediated cargo release and fluorescence activation for targeted visualization of drug delivery in breast tumors and CA-induced therapeutic effect in an <i>in vivo</i> tumor growth inhibition assay and an <i>ex vivo</i> hematoxylin and eosin (H&E) staining of tumor tissues. Thus, coencapsulation of FQ and CA into polymeric micellar nanoparticles (FQ-CA-NPs) enabled their ROS-sensitive release followed by fluorescence activation and COX-2-dependent tumor targeting and retention in the visualization of CA delivery in solid breast tumors.

Molecular PharmaceuticsVol. 22(5)
Vanderbilt University (US), Wichita State University (US), Vanderbilt University Medical Center (US)
Vanderbilt Institute for Clinical and Translational Research, National Cancer Institute
Good health and well-being
Openalex Percentile: Top 35%
Nanoparticle-Based Drug Delivery
0.60
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.